Kinshasa / Paris / Geneva / Amsterdam — • Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness
• The therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens and help support the World Health Organization's (WHO) goal of eliminating the disease by 2030
• Sanofi will donate the medicine to WHO through its philanthropic arm Foundation S
Follow us on WhatsApp | LinkedIn for the latest headlines
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion to Acoziborole Winthrop (acoziborole) as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults as well as in adolescents 12 years and older weighing at least 40 kilograms.
A positive CHMP opinion through the EU-M4all procedure provides a strong endorsement that the medicine meets EU standards. This pathway, which engages WHO disease experts and regulators from endemic countries, is reserved for high-priority medicines addressing diseases with unmet medical needs. This decision will support regulatory approval of the treatment in the Democratic Republic of Congo (DRC) and lay the groundwork for a revision of the WHO's sleeping sickness treatment guidelines. Such an update would ultimately broaden access to the medicine across other endemic countries in Central and West Africa.
Once approved in endemic countries, the medicine, co-developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, could provide a significant advance over current therapies. Existing treatments require either a 10-day course of oral medicine or a combination of injections and oral therapy for advanced cases.
'In just 20 years, we have gone from complicated treatments including arsenic derivatives with serious side effects, to today, when a single-dose, one-day therapy could safely cure patients,' said Dr Luis Pizarro, Executive Director at DNDi.
'This progress is testament to the transformative power of collaborative science and will bring us closer to finally eliminating sleeping sickness, a disease that has killed millions on the African continent in the past century.' Transmitted by the bite of an infected tsetse fly, human African trypanosomiasis, commonly known as sleeping sickness, is almost always fatal without treatment. In the early stage of the disease, people experience headaches or fever. In the late stage, the parasite crosses the blood-brain barrier and invades the central nervous system, causing behavioural, cognitive, and neurological symptoms, including seizures, sleep disturbance, aggression, confusion, lethargy, convulsions, and, ultimately, death.
DNDi conducted a pivotal Phase II/III study in the DRC and Guinea in partnership with national sleeping sickness control programmes, while Sanofi carried out the regulatory approval process. The CHMP positive opinion is based on clinical and non-clinical data provided by the partners, with efficacy and safety supported by the Phase II/III study, published in The Lancet Infectious Diseases medical journal, which demonstrated success rates at 18 months of up to 96 per cent across both stages of the disease with a good safety profile.
'The development of acoziborole and today's positive scientific opinion is a victory for Africa-led science, made possible thanks to African doctors and researchers who conducted cutting-edge pharmaceutical research in some of the most remote and difficult-to-reach areas on the continent,' said Dr Erick Miaka, Director of the DRC's national sleeping sickness control programme.
In 1998, nearly 40,000 cases of gambiense sleeping sickness were reported, with an estimated 300,000 undiagnosed. At the time, the only available treatment for those with the late stage of the disease was an injectable arsenic derivative with serious side effects. More than two decades of investment in new therapeutic tools resulted in increasingly improved treatments, including nifurtimox-eflornithine combination therapy in 2009 and the first oral treatment, fexinidazole, in 2018. In 2024, fewer than 600 cases of the disease were reported. 'For decades, Sanofi has maintained an unwavering commitment to the fight against sleeping sickness, standing alongside DNDi, the World Health Organization, and other partners in one of the most enduring and successful public-private health collaborations,' said Audrey Duval, Executive Vice President, Corporate Affairs at Sanofi. 'Together, we have helped drive cases to historic lows— achieving a remarkable 98% reduction since 2001—by putting patients first and investing in innovation where it is needed most.
Acoziborole builds on this legacy and represents a decisive step forward in eliminating gambiense sleeping sickness by 2030.' Sanofi will donate Acoziborole Winthrop to the WHO through its philanthropic organization, Foundation S – The Sanofi Collective. The medicine will be available free of charge to patients. Another study underway in the DRC and Guinea is investigating Acoziborole Winthrop for the treatment of children ages 1 to 14.
About the DNDi programme for the development of acoziborole
The DNDi programme for the development of acoziborole was supported by grants from the Federal Ministry of Research, Technology and Space (BMFTR) through KfW, Germany; the BBVA Foundation (through the 'Frontiers of Knowledge Award in Development Cooperation'); Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; European and Developing Countries Clinical Trials Partnership Association (EDCTP2 programme) supported by the European Union; Global Health EDCTP3 and its members; Gates Foundation; Médecins Sans Frontières International; Norwegian Agency for Development Cooperation (Norad), Norwegian Ministry of Foreign Affairs, as part of Norway's in-kind contribution to EDCTP2; Swiss Agency for Development and Cooperation (SDC); Swiss State Secretariat for Education, Research and Innovation (SERI); Stavros Niarchos Foundation; Spanish Agency for International Development Cooperation (AECID); UK International Development; and other private foundations and individuals.
About DNDi's sleeping sickness programme
Acoziborole Winthrop is the first oral single-dose new chemical entity to be issued from DNDi's lead optimization programme for sleeping sickness. It started with an initial hit identified in the chemical library of Anacor Pharmaceuticals, which was acquired by Pfizer in 2016. The initial structure was then optimized with Scynexis and Pace University and was then selected as a candidate for development and Phase I safety studies conducted successfully in France, the UK, and Malaysia. Acoziborole Winthrop is the latest innovation, the result of more than two decades of scientific collaboration involving DNDi, Sanofi, and partners. In 2009, they developed a combination of existing drugs known as NECT, which was extremely effective and had a good safety profile. A donation programme was
set up by Sanofi and Bayer to provide NECT free of charge to endemic countries through the World Health Organization (WHO), radically improving treatment options for patients.
DNDi, Sanofi, and partners developed fexinidazole, which in 2018 became the first all-oral treatment available for gambiense sleeping sickness. This 10-day treatment is now available in all sleeping sickness- endemic countries.
Acoziborole Winthrop can be administered as a single oral dose, potentially without the need of systemic hospitalization or supervision of the treatment at home. This means it could become a major tool to facilitate efforts to finally eliminate sleeping sickness.
About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected populations. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, river blindness, mycetoma, dengue, paediatric HIV, cryptococcal meningitis, and hepatitis C. Its research priorities include children's health; gender equity and gender-responsive R&D; and diseases impacted by climate change. Since its creation in 2003, DNDi has collaborated with public and private partners worldwide to deliver new treatments for six deadly diseases, saving millions of lives. Acoziborole is the 14th treatment delivered by DNDi. dndi.org
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
DNDi Media Relations
Frédéric Ojardias - Geneva | +41 79 431 62 16 | fojardias@dndi.org
Linet Atieno Otieno - Nairobi | +254 733 624 206| latieno@dndi.org
Ilan Moss - New York | +1 646 266 5216| imoss@dndi.org
Sanofi Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com
Sanofi Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 nina.goworek@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com
Additional quotations from partners and supporters
UK Minister for Development, Jenny Chapman said:
'Sleeping sickness is a neglected disease which affects some of the poorest communities in rural Africa. It invades the central nervous system and is almost always fatal without treatment. Not so long ago, the only treatment for sleeping sickness was a toxic injection with grim side-effects, so the development of a single-dose oral treatment is a historic milestone for combatting the disease. The UK's partnership with the Drugs for Neglected Diseases Initiative has helped deliver this breakthrough, bringing the world one step closer to eliminating sleeping sickness by 2030. We will continue backing world-class scientists, because research like this saves lives around the world.'
Director General, Africa CDC, H.E. Dr. Jean Kaseya said:
'This breakthrough brings Africa closer to eliminating sleeping sickness and reflects the growing strength of African scientific leadership. The next step is to ensure innovation translates into sustainable access for the communities most at risk. Africa CDC supports efforts to explore producing treatments like acoziborole in Africa—advancing pharmaceutical manufacturing, strengthening supply resilience, and reinforcing Africa's health security, consistent with Africa CDC's drive to expand local production capacity across the continent.'
African Union Commissioner for Health, Humanitarian Affairs and Social Development, H.E. Amb. Amma Adoma Twum-Amoah said:
'Today marks a historic victory for health equity in Africa. We are turning what once required hospital beds into a simple cure, removing the last mile barriers to ending sleeping sickness for good. This milestone proves that when global solidarity meets African leadership, innovation does not remain in laboratories, it reaches villages, families and the very heart of our communities.'
L'ambassadrice santé mondiale pour la France, Anne-Claire Amprou, a déclaré:
« La France félicite DNDi et Sanofi pour cette nouvelle étape franchie dans la lutte contre la maladie du sommeil. Fruit de l'innovation médicale, le développement de l'acoziborole, médicament révolutionnaire permettant de lutter contre cette maladie parasitaire, marque un moment décisif pour protéger les communautés et patients situés au cœur des régions endémiques de cette maladie. Mettre l'expertise scientifique française au service de la lutte contre les maladies vectorielles, notamment par la mise en œuvre de l'approche « Une seule Santé », est un axe prioritaire de la stratégie française en santé mondiale 2023 – 2027 et du One Health Summit qui se tiendra à Lyon, le 7 avril 2026. »
Executive Director, Global Health EDCTP3, Dr Michael Makanga said:
'The development of acoziborole is a powerful exemplar of how sustained investment in locally-led clinical research creates high-impact solutions for the most vulnerable populations – here people at risk of sleeping sickness in all settings, even in the most remote communities. Building on the paediatric evidence from the EDCTP2-funded ACOZI-KIDS project and now the StrogHAT consortium supported by Global Health EDCTP3, evaluations are in full swing to turn a one-dose oral cure into a practical screen- and-treat tool that can interrupt transmission and bring us closer to eliminating gambiense human African trypanosomiasis by 2030.'
L'ambassadeur de l'Union européenne en Guinée, Xavier Sticker, a salué cette innovation :
« La lutte contre la maladie du sommeil fait aujourd'hui un nouveau pas en avant grâce à un partenariat d'acteurs de l'Equipe Europe, incluant des organisations non gouvernementales et le secteur privé. Avec l'arrivée de l'acoziborole, il suffira de prendre une seule dose pour le traitement de cette maladie endémique. Ainsi, le diagnostic et le traitement pourront être administrés conjointement et facilement sur place. En Guinée, la maladie du sommeil était un problème sanitaire majeur depuis longtemps. Grâce à une collaboration entre les services publics, la communauté scientifique, les chercheurs et les organisations de la société civile, cette maladie a pu être reconnue il y a un an par l'Organisation mondiale de la santé comme ne constituant plus un problème de santé publique. Grâce à cette innovation européenne qu'est l'acoziborole, une étape supplémentaire pourra être franchie : la prise en charge des cas résiduels sera facilitée et toute résurgence de la maladie sera contenue, avant que l'on parvienne à son éradication complète. Cette solution européenne, validée aujourd'hui par l'EMA, est porteuse d'espoir pour la population en Guinée et au niveau mondial. L'Équipe Europe demeure un acteur fortement engagé dans le secteur de la santé en Guinée, à travers le renforcement d'un système de santé de qualité, au service de l'ensemble de la population. »
Sanofi forward-looking statements
Sign up for free AllAfrica Newsletters
Get the latest in African news delivered straight to your inbox
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events,operations, services, product development and potential, and statements regarding future events and economic performance. Words such as "expect," "anticipate," "believe," "intend," "estimate," "plan," "can," "contemplate," "could," "is designed to," "may," "might," "potential," "objective," "attempt," "target," "project," "strategy," "strive," "desire," "predict," "forecast," "ambition," "guideline," "seek," "should," "will," "goal," or the negative of these, and similar expressions are intended to identify forward-looking statements. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities' decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including "most favored nation" pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation; trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markest Authority (AMF) made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward- looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.
